Navigation Links
Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence
Date:9/11/2013

A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) a biomarker based on the expression levels of seven tumor-specific genes accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole. The study comparing the BCI with two other prognostic tests has been published online in Lancet Oncology.

"We have validated a unique 'fingerprint' in the primary tumor of breast cancer patients that can help identify a high or low risk of cancer recurrence," says study co-author Paul Goss, MD, PhD, director of the Breast Cancer Research Program at Massachusetts General Hospital (MGH) Cancer Center. "This should enable us to offer prolonged treatment to patients who remain at risk and, importantly, to avoid the costs and side effects of treatment in those at low risk."

Standard treatment for early-stage, ER-positive breast cancer includes five years of treatment with either tamoxifen or an aromatase inhibitor, drugs that block the action of estrogen. While that approach is sufficient for most patients, some continue to experience recurrence during subsequent years. The study authors note that knowing whether or not a patient continues to be at risk is essential to determining whether prolonged treatment is necessary.

MGH researchers previously developed, in collaboration with investigators from bioTheranostics, Inc., two biomarkers for recurrence risk assessment the molecular grade index, which measures expression levels of five genes related to tumor proliferation; and the H/I ratio, which compares expression levels of two other genes. BCI is a combination of both biomarkers and has been shown to identify patients who are at risk of early recurrence despite receiving hormonal treatment.

The current study, led by Dennis Sgroi, MD, of the MGH Cancer Center and Department of Pathology, was designed to compare the ability of the BCI to predict long-term recurrence risk with that of two other gene-expression signatures that can predict risk in the first five years the Oncotype Dx Recurrence Score, the current gold standard for guiding clinical decision making, and the less frequently used ICH4 gene signature. All three methods were used to analyze primary tumor samples from more than 650 participants in a clinical trial comparing tamoxifen with anastrozole. Assay results were compared with patient records to determine individual rates of recurrence up to 10 years after initial surgical treatment.

While all three methods were able to predict recurrence risk in the first five years, only the BCI was able to accurately assess long-term recurrence risk. In fact, the BCI was able to clearly distinguish 60 percent of patients whose risk was quite low from 40 percent who continued to be at significant long-term risk. "We know that more than half the instances of recurrence in ER-positive breast cancer occur after five years of therapy with tamoxifen or anastrozole, so these findings are highly relevant to clinical management," says Sgroi. "Since the BCI identifies two distinct risk groups, it may provide a much-needed tool in determining those patients who need extended hormonal therapy and those who may be spared its well-known adverse side effects."


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Researchers to identify genetic biomarkers for aggressive breast cancer
2. Study identifies fibroblast growth factor 18 as an ovarian cancer biomarker
3. Biomarker assessment in suspected ACS could be practice-changing: BIC-8 results
4. Researchers develop specific tests to identify cancer biomarkers in dermatomyositis
5. Global Oncology Biomarkers Market to Reach US $9.5 Billion by 2014 at a CAGR of 18.1% - New Report by MarketsandMarkets
6. Biomarker Market is Estimated to Grow at a CAGR of 14.40% During the Study Period of 2011-2016 – New Report by MarketsandMarkets
7. Research points to biomarker that could track Huntingtons disease progression
8. Urine biomarker test can diagnose as well as predict rejection of transplanted kidneys
9. Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment
10. New concussion data: 2 biomarkers better than 1
11. MET protein levels show promise as biomarker for aggressive colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... ... announced it has been included by Gartner, Inc. in the Contact Center Infrastructure ... of Contact Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web ...
(Date:5/31/2016)... ... May 31, 2016 , ... The University of ... Intelligence (AI) and the latest in Clinical Patient Pod (CPP) technologies ... analytic outputs directly into the clinical workflow. These insights are empowering the more ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... commercial molecular diagnostics device that enables unprecedented portability and convenience. , The Cube ... four inches cubed in size, the Cube fits easily into any space, whether ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit ... predictions on the future of wellness, travel, spa and beauty in Europe. The organization ... beauty companies to leading economists and researchers - to forecast where wellness is headed ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation ... , David G. Lewallen, MD, began his term as president in March, succeeding John ... MD, is OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 2016 PaperHive Will Enable ... Elsevier,s ScienceDirect Database Elsevier , ... information products and services, today announced it will ... collaboration platform PaperHive to enable researchers to easily discover, ... on ScienceDirect , the world,s largest database ...
(Date:5/31/2016)... , Isansys  Lifecare, a new generation digital healthcare company, ... patient monitoring platform, as it ships more systems to hospitals in ... Scotland and Norway , ... earlier this year, is now being used in ground-breaking clinical ... new technology significantly enhances the user experience and provides higher ...
(Date:5/30/2016)... York , May 30, 2016 ... report titled, "Advanced (3D/4D) Visualization Systems Market - Global ... - 2024." According to the report, the global advanced ... Bn in 2015 and is anticipated to expand at ... reach US$ 3.2 Bn in 2024. Advanced ...
Breaking Medicine Technology: